Friday, 18 July 2025
  
Login

Australia's most trusted
source of pharma news

Friday, 18 July 2025
News

Why this CEO can't help smiling

Posted 18 July 2025 AM

Johnson & Johnson Innovative Medicine has seen off the threat of Stelara losing patent protection, with record-breaking revenue of more than US$15 billion last quarter across its pharmaceutical portfolio.

Total revenue for the Innovative Medicine segment grew 4.9 per cent in the second quarter of 2025 compared to the same period in 2024, adding US$712 million in sales and surpassing US$15 billion for the first time.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (15)

Clinical & Medical, R&D (8)

Regulatory, Pharmacovigilance & QA (4)

Devices (1)

Other (17)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.